Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Deric L. Wheeler"'
Autor:
Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler
Publikováno v:
BMC Cancer. 22
Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for tre
Autor:
Colin Longhurst, Lindsey Abel, Arda Durmaz, Rong Hu, Randall J. Kimple, Jacob G. Scott, Deric L. Wheeler, Andrew M. Baschnagel
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-8 (2021)
Journal of Translational Medicine
Journal of Translational Medicine
Background Patient-derived xenografts established from human cancers are important tools for investigating novel anti-cancer therapies. Establishing PDXs requires a significant investment and many PDXs may be used infrequently due to their similarity
Autor:
Samantha R. Fischbach, Kaitlyn R. Mitchell, Seungpyo Hong, Tamara S. Rodems, Deric L. Wheeler, Alison E. Schulz, Jaimee C. Eckers, Ravi Salgia, Qianyun Luo, Colin Longhurst, Noah B. Welke, Justine Yang Bruce, Nellie K. McDaniel, Carlene A. Kranjac, Amber Bo, Randall J. Kimple, Kwangok P. Nickel, Rong Hu, Meghan M. Gallagher, Mari Iida
Publikováno v:
Clin Cancer Res
Purpose: Radiation and cetuximab are therapeutics used in management of head and neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development of both intrinsic and acquired resistance is an emerging problem in the
Autor:
Harsh Bahrar, John P. Coan, Toni M. Brand, Johan Lantto, Michael Kragh, Rachel A. Orbuch, Hannah E. Pearson, Deric L. Wheeler, Adam D. Swick, Mari Iida, Prashanth J. Prabakaran, Bailey Flanigan, Randall J. Kimple, Ivan D. Horak, Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics, 15, 2175-86
Molecular Cancer Therapeutics, 15, 9, pp. 2175-86
Molecular Cancer Therapeutics, 15, 9, pp. 2175-86
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non–small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do
Autor:
Randall J. Kimple, Kwangok P. Nickel, Ravindra Uppaluri, Loren S. Michel, Anthony M. Robinson, Brian A. Van Tine, Douglas Adkins, Nathan J. Redlich, Deric L. Wheeler, Andrew P. Stein
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 9, Iss 1, Pp 1-12 (2018)
Cell Death and Disease, Vol 9, Iss 1, Pp 1-12 (2018)
ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear. Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought to signal indepen
Autor:
Rong Hu, Adam D. Swick, Michael M. Fisher, Randall J. Kimple, Amal M. Javaid, Kwangok P. Nickel, Prashanth J. Prabakaran, Mari Iida, Deric L. Wheeler, Emmanuel Sampene, Irene M. Ong, Justine Yang Bruce, Margot C. Miller
Head and neck squamous cell carcinomas (HNSCC) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds targeting this pathway as monotherapy has been underwhelming in initial clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa1a5bf18a478f48e0af5c9c3dac743
https://europepmc.org/articles/PMC5505754/
https://europepmc.org/articles/PMC5505754/
Autor:
Deric L. Wheeler, Shyhmin Huang, Alexander Chi, Sergi Benavente, Paul M. Harari, Kun-Tai Hsu, Eric A. Armstrong
Publikováno v:
Clinical Cancer Research. 15:1585-1592
Purpose: The epidermal growth factor receptor (EGFR) is recognized as a key mediator of proliferation and progression in many human tumors. A series of EGFR-specific inhibitors have recently gained Food and Drug Administration approval in oncology. T
Autor:
Vassiliki Saloura, David T. Yang, John P. Coan, Randall J. Kimple, Victoria M. Villaflor, Toni M. Brand, Cara M. Braverman, Mark W. Lingen, Mari Iida, Parkash S. Gill, Hannah E. Pearson, Kelsey L. Corrigan, Andrew P. Stein, Bryan Bednarz, Sandeep Saha, Harsh Bahrar, Ravi Salgia, Tyler L. Fowler, Deric L. Wheeler
Purpose: Head and neck squamous cell carcinoma (HNSCC) represents the eighth most common malignancy worldwide. Standard-of-care treatments for patients with HNSCC include surgery, radiation, and chemotherapy. In addition, the anti-EGFR monoclonal ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5bccd84854156c4659c665e582fc78
https://europepmc.org/articles/PMC5032632/
https://europepmc.org/articles/PMC5032632/
Autor:
Chunrong, Li, Toni M, Brand, Mari, Iida, Shyhmin, Huang, Eric A, Armstrong, Albert, van der Kogel, Deric L, Wheeler
Publikováno v:
Discovery medicine. 16(87)
HER3 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. In the present study, we investigated the capacity of the HER3 blocking antibody, U3-1287/AMG888, to modulate the in vitro and in vivo radiation resp
Autor:
Marieke M G Verheijen, Johannes H.A.M. Kaanders, Albert J. van der Kogel, Hanneke Stegeman, Paul N. Span, Johan Bussink, Mari Iida, Wenny J.M. Peeters, Deric L. Wheeler, Reidar Grénman
Publikováno v:
Molecular Cancer
Background: Kinases downstream of growth factor receptors have been implicated in radioresistance and are, therefore, attractive targets to improve radiotherapy outcome in head and neck squamous cell carcinoma (HNSCC) patients. Methods: An antibody-b